896 related articles for article (PubMed ID: 1906017)
21. Phase I comparative clinical trial with subdermal implants--bioabsorbable levonorgestrel or norethisterone pellet fused with cholesterol.
Joshi UM; Joshi JV; Donde UM; Sankoli GM; Virkar KD; Saxena BN
Contraception; 1985 Jan; 31(1):71-82. PubMed ID: 3921309
[TBL] [Abstract][Full Text] [Related]
22. Hormonal consequences of missing the pill during the first two days of three consecutive artificial cycles.
Landgren BM; Diczfalusy E
Contraception; 1984 May; 29(5):437-46. PubMed ID: 6430642
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of ovulation by progestin analogs (agonists vs antagonists): preliminary evidence for different sites and mechanisms of actions.
Heikinheimo O; Gordon K; Williams RF; Hodgen GD
Contraception; 1996 Jan; 53(1):55-64. PubMed ID: 8631191
[TBL] [Abstract][Full Text] [Related]
24. Modulation of ovarian function by an oral contraceptive containing 30 micrograms ethinyl estradiol in combination with 2.00 mg dienogest.
Spona J; Feichtinger W; Kindermann C; Moore C; Mellinger U; Walter F; Gräser T
Contraception; 1997 Sep; 56(3):185-91. PubMed ID: 9347211
[TBL] [Abstract][Full Text] [Related]
25. Pituitary and ovarian function in women receiving hormonal contraception.
Cohen BL; Katz M
Contraception; 1979 Nov; 20(5):475-87. PubMed ID: 393456
[TBL] [Abstract][Full Text] [Related]
26. Interruption of endometrial maturation without hormonal changes by an antiprogesterone during the first half of luteal phase of the menstrual cycle: a contraceptive potential.
Greene KE; Kettel LM; Yen SS
Fertil Steril; 1992 Aug; 58(2):338-43. PubMed ID: 1633899
[TBL] [Abstract][Full Text] [Related]
27. The effect of deliberate omission of Trinordiol or Microgynon on the hypothalamo-pituitary-ovarian axis.
Smith SK; Kirkman RJ; Arce BB; McNeilly AS; Loudon NB; Baird DT
Contraception; 1986 Nov; 34(5):513-22. PubMed ID: 3102162
[TBL] [Abstract][Full Text] [Related]
28. Effects of low dose oral contraceptives containing norethindrome and ethinyl estradiol on serum levels of progesterone and pituitary gonadotropins.
McGuire JL; Bariso CD; Yuliano E; Hume RJ; Pasquale SA
Contraception; 1975 Mar; 11(3):329-38. PubMed ID: 1116369
[TBL] [Abstract][Full Text] [Related]
29. Metabolic changes during treatment with two different progestogens.
Refn H; Kjaer A; Lebech AM; Borggaard B; Schierup L; Bremmelgaard A
Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):374-7. PubMed ID: 2115298
[TBL] [Abstract][Full Text] [Related]
30. Timing of onset of contraceptive effectiveness in Norplant implant users. Part I. Changes in cervical mucus.
Dunson TR; Blumenthal PD; Alvarez F; Brache V; Cochon L; Dalberth B; Glover L; Remsburg R; Vu K; Katz D
Fertil Steril; 1998 Feb; 69(2):258-66. PubMed ID: 9496339
[TBL] [Abstract][Full Text] [Related]
31. Effect of norethindrone acetate released from a single silastic implant on serum FSH, LH, progesterone and estradiol-17beta of women during first eight months of treatment.
Rahman SA; Jha P; Laumas V; Jain AK; Dileepkumar ; Takkar D; Hingorani V; Laumas KR
Contraception; 1977 Nov; 16(5):487-97. PubMed ID: 590011
[TBL] [Abstract][Full Text] [Related]
32. Hormonal treatment for bleeding irregularities in Norplant implant users.
Alvarez-Sanchez F; Brache V; Thevenin F; Cochon L; Faundes A
Am J Obstet Gynecol; 1996 Mar; 174(3):919-22. PubMed ID: 8633669
[TBL] [Abstract][Full Text] [Related]
33. Serum concentrations of estradiol, progesterone, and levonorgestrel are not determinants of endometrial histology or abnormal bleeding in long-term Norplant implant users.
Darney PD; Taylor RN; Klaisle C; Bottles K; Zaloudek C
Contraception; 1996 Feb; 53(2):97-100. PubMed ID: 8838486
[TBL] [Abstract][Full Text] [Related]
34. Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.
Lemay A; Faure N
J Clin Endocrinol Metab; 1986 Dec; 63(6):1379-85. PubMed ID: 2946711
[TBL] [Abstract][Full Text] [Related]
35. Suppression of ovarian function by Microgynon 30 in day 1 and day 5 "starters".
Taylor DR; Anthony FW; Dennis KJ
Contraception; 1986 May; 33(5):463-71. PubMed ID: 3757512
[TBL] [Abstract][Full Text] [Related]
36. Interference with ovulation by sequential treatment with the antiprogesterone RU486 and synthetic progestin.
Kekkonen R; Alfthan H; Haukkamaa M; Heikinheimo O; Luukkainen T; Lähteenmäki P
Fertil Steril; 1990 Apr; 53(4):747-50. PubMed ID: 2108063
[TBL] [Abstract][Full Text] [Related]
37. Mode of action of dl-norgestrel and ethinylestradiol combination in postcoital contraception. II. Effect of postovulatory administration on ovarian function and endometrium.
Ling WY; Wrixon W; Zayid I; Acorn T; Popat R; Wilson E
Fertil Steril; 1983 Mar; 39(3):292-7. PubMed ID: 6402387
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.
Lemay A; Faure N; Labrie F; Fazekas AT
Fertil Steril; 1985 Jun; 43(6):868-77. PubMed ID: 3158551
[TBL] [Abstract][Full Text] [Related]
39. Immunohistochemical staining of von Willebrand factor in endometrium of women during the first year of Norplant implants use.
Au CL; Affandi B; Rogers PA
Contraception; 1994 Nov; 50(5):477-89. PubMed ID: 7859456
[TBL] [Abstract][Full Text] [Related]
40. Effect of daily administration of 0.5 mg. of chlormadinone acetate on plasma levels of follicle-stimulating hormone, luteinizing hormone, and progesterone during the menstrual cycle.
Saunders DM; Marcus SL; Saxena BB; Beling CG; Connell EB
Fertil Steril; 1971 May; 22(5):332-44. PubMed ID: 4102481
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]